Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F520 in relapsed/refractory CNS lymphoma
CTR20201338Phase 2Terminated
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rulonilimab in primary central nervous system lymphoma (PCNSL), central nervous system lymphoma, sponsored by Shandong New Era Pharmaceutical. Started Aug 2020; status: terminated.
02
Drugs
rulonilimab
03
Conditions
primary central nervous system lymphoma (PCNSL)central nervous system lymphoma
Beyond the preview
Go deeper on CTR20201338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201338.